PharmaBlock has opened a new R&D facility in Pennsylvania, expanding its capacity to deliver GMP projects.
PharmaBlock, a contract development and manufacturing organization focused on innovative chemistry and low-carbon manufacturing, announced on March 27, 2023 the opening of its new R&D facility in West Chester, Pa. The facility will expand the company’s footprint in the United States and increase its capacity to delivery good manufacturing practice (GMP) projects to global partners.
The new site includes 30,000 ft2 of lab space and includes process R&D labs, GMP suites, clean rooms, and GMP analytical labs. The site also enables flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities. The site joins the company’s existing facility in Hatfield, Pa., and is a crucial addition to enhancing the delivery of clinical-stage API projects, according to a company press release.
"We are excited to celebrate the grand opening of our new research facility, which represents a significant milestone for our company," said Jing Li, president of PharmaBlock, in the release. "This state-of-the-art facility will enable us to provide our clients with the highest quality research and development solutions, and we look forward to continuing to innovate and advance."
Source: PharmaBlock
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.